2024-12-19 - Analysis Report
## TDOC (Teladoc Health Inc) Stock Analysis

**1. Performance vs. S&P 500:**

TDOC has significantly underperformed the S&P 500.  The cumulative return for TDOC is -65.00%, while the S&P 500 (VOO) has returned 120.80%. This represents a difference of -185.80 percentage points.  The relative divergence of 0.2 indicates that TDOC's performance is near the bottom of its historical range compared to the S&P 500.

Teladoc Health Inc. is a telehealth company providing virtual healthcare services.

The provided alpha and beta analysis shows consistently high alpha in earlier years, transitioning to significantly negative alpha in recent years. This suggests diminishing outperformance and then substantial underperformance compared to the market.  The consistent beta of 0.0 is unusual and might indicate a data issue or a specific calculation method.  The market capitalization has also drastically declined.

**2. Recent Price Action:**

TDOC's current price ($10.07) is slightly above the last market price of $10.05. Short-term moving averages are indicating a downward trend: 5-day MA ($10.39), 20-day MA ($10.71).  However, the 60-day MA ($9.63) is below the current price, suggesting a potential longer-term upward trend.

**3. Technical Indicators:**

* RSI (33.91): Suggests the stock is approaching oversold territory, potentially signaling a buying opportunity.
* PPO (-1.4793): A negative PPO indicates bearish momentum.
* Recent Relative Divergence Change (-0.3): Confirms the short-term downward trend against the S&P 500.
* Expected Return (0.0%):  Indicates no expected outperformance against the S&P 500 over the long term.

**4. Recent Earnings Analysis:**

* **Latest Quarter Comparison:**  Revenue has remained relatively flat over the past few quarters around $0.64B - $0.66B. EPS has fluctuated significantly, with a large loss in Q2 2024 (-$4.92).
* **Revenue Growth Trends:**  Revenue shows a slight declining trend over the past year.
* **EPS Trends:** EPS has been volatile and generally negative, with a particularly concerning result in Q2 2024.  There's no consistent trend towards improvement.
* **Beats or Misses:** The data doesn't provide expectations, so it's impossible to determine beats or misses.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue remains relatively stable, but profit margins, while high (around 70%), don't seem to translate into positive net income (as indicated by negative EPS). This discrepancy requires further investigation.
* **Capital and Profitability:**  Equity has decreased over the past year. ROE is consistently negative and highly volatile, indicating poor profitability relative to equity. The substantial negative ROE in Q2 2024 (-55.77%) is particularly alarming.

**6. News and Recent Issues:**

The prompt mentions recent earnings news, market outlook, and analyst opinions, but doesn't provide specifics. This information is crucial for a comprehensive analysis.  Please provide the details for a more accurate assessment.


**7. Summary:**

TDOC is facing significant challenges. The stock has drastically underperformed the market, recent price action shows a downward trend, and technical indicators suggest bearish momentum. While revenue remains relatively stable, profitability is a major concern, evidenced by negative EPS and ROE. The significant drop in ROE in Q2 2024 warrants further scrutiny.  Without more context regarding news, analyst opinions, and recent market outlook, a complete assessment is difficult. However, the available data paints a concerning picture for TDOC.

**8. Overall Recommendation:**

Based on the available information, TDOC appears to be a risky investment.  Further investigation is needed, particularly regarding the reasons for the discrepancies between high profit margins and negative earnings, the significant negative ROE, and the recent news and analyst opinions.  Until these concerns are addressed and a clear path to profitability is established, caution is advised.
